Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-11312737-B2
Application number	US-201916518132-A
Country	US
Kind code	B2
Filing date	Jul 22, 2019
Priority date	Jun 12, 2015
Publication date	Apr 26, 2022
Grant date	Apr 26, 2022

Abstract

The present invention relates to EP4 agonist-bisphosphonate conjugates or related compounds and uses thereof. Said conjugates or related compounds may be used to provide delivery of an EP4 agonist or related compound to a desired site of action, such as a bone. Bisphosphonate moieties, linked to the EP4 agonists via amide linkers, have been implicated in the inhibition of bone resorption and bone targeting.

First claim

What is claimed is:

1. A compound, or a pharmaceutically acceptable salt thereof, the compound comprising at least one EP4 agonist or related compound linked to an amide linker through an ester bond and an amino bisphosphonate linked to the amide linker through an amide bond,
wherein the EP4 agonist or related compound is selected from

and wherein the amide linker comprises a structure selected from

wherein
R3 is each independently H, OR′, halogen, CN, or C(O)R′,
R′ is each independently H or alkyl with one to ten carbon atoms, or the two R's form a ring of up to 6 carbons,
NHR″, if present, is the amino group of the amino bisphosphonate,
q, if present, is 1 or 2,
n, if present, is 1, 2 or 3,
and

wherein one or more of the aliphatic carboxylic acid groups can react with the C-15 hydroxyl group of the EP4 agonist or related compound, to form the ester bond, and the remaining carboxylic acid group can react with the amino group of the amino bisphosphonate to form the amide bond.

2. The compound of claim 1 wherein the compound is hydrolyzable in vivo.

3. The compound of claim 2 wherein the compound is inactive prior to hydrolyzation.

4. The compound of claim 1 wherein the amide bond is resistant to hydrolysis in vivo.

5. A pharmaceutical composition comprising the compound of claim 1 , in combination with a pharmaceutically acceptable carrier.

6. A method of selectively delivering a compound to bone, the method comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.

7. The method of claim 6 wherein the bone is a bone in need of treatment.

8. The method of claim 7 wherein the bone in need of treatment is selected from the group consisting of a green stick fracture, compound fracture, lateral fracture, pathologic fracture resulting from an invasive tumor, compression fracture, and fracture requiring a surgical procedure for realignment of a bone.

9. The method of claim 6 wherein the compound is hydrolyzed after binding to bone.

10. The method of claim 9 wherein the compound is inactive prior to hydrolyzation.

11. The method of claim 9 wherein the compound releases an active agent after hydrolyzation.

12. The method of claim 11 wherein the active agent is the EP4 agonist or related compound.

13. The method of claim 9 wherein the bisphosphonate moiety remains attached to the bone.

14. The method of claim 6 wherein the subject is a human.

15. A method of preparing a compound according to claim 1 , comprising:
i) providing at least one EP4 agonist or related moiety comprising a hydroxyl group, an amide linker comprising at least two carboxylic acid groups, and a bisphosphonate moiety comprising an amino group;
ii) reacting one of the carboxylic acid groups of the amide linker with the hydroxyl group of the EP4 agonist or related moiety, to form an ester bond, and
iii) reacting the other carboxylic acid of the amide linker group with the amino group of the bisphosphonate to form an amide bond.

16. The compound of claim 1 wherein the amide linker is 4-(carboxymethyl) benzoic acid or 3,5-bis-(carboxymethyl)benzoic acid.

17. The compound of claim 1 wherein the amino bisphosphonate has the following structure:

wherein m is 1, 2, 3, 4, 5 or 6.

18. The compound of claim 1 wherein the amino bisphosphonate is alendronic acid, 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid; alendronate, 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid monosodium trihydrate, 6-amino-1-hydroxyhexylidene-1, 1-bisphosphonic acid, or 3-amino-1-hydroxypropylidene-1, 1-bisphosphonic acid.

19. The compound of claim 1 wherein the EP4 agonist or related compound is

Assignees

• Univ Fraser Simon

Inventors

• Thévenin Marion
• Young Robert N
• Chen Gang

Classifications

• A61K47/548

  Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544) · CPC title

• C07F9/572 Primary

  Five-membered rings · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title

• C07F9/3873

  containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S) · CPC title